Any progress in pancreatic cancer?

References

• Glimelius B. Any progress in pancreatic cancer? Well, but progress for Acta Oncologica. Acta Oncol 2010;49:404–6.
   PubMed Web of Science ®Google Scholar
• Simianu VV, Zyromski NJ, Nakeeb A, Lillemoe KD. Pancreatic cancer: progress made. Acta Oncol 2010;49:407–17.
   PubMed Web of Science ®Google Scholar
• Zijlstra M, Bernards N, de Hingh IH, van de Wouw AJ, Goey SH, Jacobs EM, et al. Does long-term survival exist in pancreatic adenocarcinoma? Acta Oncol 2016;55:259--64.
   PubMed Web of Science ®Google Scholar
• Lepage C, Capocaccia R, Hackl M, Lemmens V, Molina E, Pierannunzio D, et al. Survival in patients with primary liver cancer, gallbladder and extrahepatic biliary tract cancer and pancreatic cancer in Europe 1999-2007: Results of EUROCARE-5. Eur J Cancer 2015; 10.1016/j.ejca.2015.07.034.
   PubMed Web of Science ®Google Scholar
• Lambe M, Eloranta S, Wigertz A, Blomqvist P. Pancreatic cancer; reporting and long-term survival in Sweden. Acta Oncol 2011;50:1220–7.
   PubMed Web of Science ®Google Scholar
• Speer AG, Thursfield VJ, Torn-Broers Y, Jefford M. Pancreatic cancer: surgical management and outcomes after 6 years of follow-up. Med J Aust 2012;196:511–15.
   PubMed Web of Science ®Google Scholar
• Soreide K, Aagnes B, Moller B, Westgaard A, Bray F. Epidemiology of pancreatic cancer in Norway: trends in incidence, basis of diagnosis and survival 1965-2007. Scand J Gastroenterol 2010;45:82–92.
   PubMed Web of Science ®Google Scholar
• Krilaviciute A, Smailyte G, Brenner H, Gondos A. Cancer survival in Lithuania after the restoration of independence: rapid improvements, but persisting major gaps. Acta Oncol 2014;53:1238–44.
   PubMed Web of Science ®Google Scholar
• Bjerregaard J, Mortensen MB, Pfeiffer P. Trends in cancer of the liver, gall bladder, bile duct, and pancreas in elderly in Denmark, 1980-2012. Acta Oncol 2016;55(Supplement 1):40--5.
   PubMedGoogle Scholar
• Kilander C, Mattsson F, Ljung R, Lagergren J, Sadr-Azodi O. Systematic underreporting of the population-based incidence of pancreatic and biliary tract cancers. Acta Oncol 2014;53:822–9.
   PubMed Web of Science ®Google Scholar
• Nilsson M, Tavelin B, Axelsson B. A study of patients not registered in the Swedish Cancer Register but reported to the Swedish Register of Palliative Care 2009 as deceased due to cancer. Acta Oncol 2014;53:414–19.
   PubMed Web of Science ®Google Scholar
• Bernards N, Haj Mohammad N, Creemers GJ, de Hingh IH, van Laarhoven HW, Lemmens VE. Ten weeks to live: a population-based study on treatment and survival of patients with metastatic pancreatic cancer in the south of the Netherlands. Acta Oncol 2015;54:403–10.
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817–25.
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:1691–703.
   PubMed Web of Science ®Google Scholar
• Anshushaug M, Gynnild MA, Kaasa S, Kvikstad A, Gronberg BH. Characterization of patients receiving palliative chemo- and radiotherapy during end of life at a regional cancer center in Norway. Acta Oncol 2015;54:395–402.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 2009;27:5513–18.
   PubMed Web of Science ®Google Scholar
• Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schuller J, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 2007;25:2212–17.
   PubMed Web of Science ®Google Scholar
• Goldstein D, El-Maraghi RH, Hammel P, Heinemann V, Kunzmann V, Sastre J, et al. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Natl Cancer Inst 2015;107:(2)dju413.
   Google Scholar
• Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350:1200–10.
   PubMed Web of Science ®Google Scholar
• Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. Jama 2007;297:267–77.
   PubMed Web of Science ®Google Scholar
• Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. Jama 2013;310:1473–81.
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. Jama 2010;304:1073–81.
   PubMed Web of Science ®Google Scholar
• Labori KJ, Katz MH, Tzeng CW, Bjornbeth BA, Cvancarova M, Edwin B, et al. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study. Acta Oncol 2016;55:265--77.
   PubMed Web of Science ®Google Scholar
• van der Geest LG, Besselink MG, van Gestel YR, Busch OR, de Hingh IH, de Jong KP, et al. Pancreatic cancer surgery in elderly patients: Balancing between short-term harm and long-term benefit. A population-based study in the Netherlands. Acta Oncol 2016;55:278--85.
   PubMed Web of Science ®Google Scholar
• Mellon EA, Hoffe SE, Springett GM, Frakes JM, Strom TJ, Hodul PJ, et al. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. Acta Oncol 2015;54:979–85.
   PubMed Web of Science ®Google Scholar
• Kelly CM, El Bassiouni M, Bennett MW, Crush L, Mceneaney P, O'suilleabhain C, et al. Borderline resectable pancreatic adenocarcinoma, is conversion therapy realistic? Acta Oncol 2014;53:1268–71.
   PubMed Web of Science ®Google Scholar
• Oyasiji T, Ma WW. Novel adjuvant therapies for pancreatic adenocarcinoma. J Gastrointest Oncol 2015;6:430–5.
   PubMed Web of Science ®Google Scholar
• Nichols RC, Jr, George TJ, Zaiden RA, Jr, Awad ZT, Asbun HJ, Huh S, et al. Proton therapy with concomitant capecitabine for pancreatic and ampullary cancers is associated with a low incidence of gastrointestinal toxicity. Acta Oncol 2013;52:498–505.
   PubMed Web of Science ®Google Scholar
• Lens E, van der Horst A, Kroon PS, van Hooft JE, Davila Fajardo R, Fockens P, et al. Differences in respiratory-induced pancreatic tumor motion between 4D treatment planning CT and daily cone beam CT, measured using intratumoral fiducials. Acta Oncol 2014;53:1257–64.
   PubMed Web of Science ®Google Scholar
• Sangalli G, Passoni P, Cattaneo GM, Broggi S, Bettinardi V, Reni M, et al. Planning design of locally advanced pancreatic carcinoma using 4DCT and IMRT/IGRT technologies. Acta Oncol. 2011;50:72–80.
   PubMed Web of Science ®Google Scholar
• Warren S, Partridge M, Fokas E, Eccles CL, Brunner TB. Comparing dose-volume histogram and radiobiological endpoints for ranking intensity-modulated arc therapy and 3D-radiotherapy treatment plans for locally-advanced pancreatic cancer. Acta Oncol. 2013;52:1573–8.
   PubMed Web of Science ®Google Scholar
• Kruger S, Boeck S, Heinemann V, Laubender RP, Vehling-Kaiser U, Waldschmidt D, et al. Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced pancreatic cancer: a subgroup analysis from AIO-PK0104. Acta Oncol 2015;54:993–1000.
   PubMed Web of Science ®Google Scholar
• Larsen FO, Mellergaard AH, Hoegdall DT, Jensen LH. Gemcitabine, capecitabine and oxaliplatin in advanced biliary tract carcinoma. Acta Oncol. 2014;53:1448–50.
   PubMed Web of Science ®Google Scholar
• Larsen FO, Taksony D, Hoegdall S, Hoegdall E, Nielsen D. Gemcitabine, capecitabine and oxaliplatin with or without cetuximab in advanced biliary tract carcinoma. Acta Oncol 2016;55:382--85.
   Google Scholar
• Philip PA, Benedetti J, Corless CL, Wong R, O'reilly EM, Flynn PJ, et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 2010;28:3605–10.
   PubMed Web of Science ®Google Scholar
• Elebro J, Ben Dror L, Heby M, Nodin B, Jirstrom K, Eberhard J. Prognostic effect of hENT1, dCK and HuR expression by morphological type in periampullary adenocarcinoma, including pancreatic cancer. Acta Oncol 2016;55:286--96.
   PubMed Web of Science ®Google Scholar
• Chadha AS, Kocak-Uzel E, Das P, Minsky BD, Delclos ME, Mahmood U, et al. Paraneoplastic thrombocytosis independently predicts poor prognosis in patients with locally advanced pancreatic cancer. Acta Oncol 2015;54:971–8.
   PubMed Web of Science ®Google Scholar
• Sharma MB, Carus A, Sunde L, Hamilton-Dutoit S, Ladekarl M. BRCA-associated pancreatico-biliary neoplasms: Four cases illustrating the emerging clinical impact of genotyping. Acta Oncol 2016;55:377--81.
   PubMed Web of Science ®Google Scholar
• Reni M, Wan Y, Solem C, Whiting S, Ji X, Botteman M. Quality-adjusted survival with combination nab-paclitaxel + gemcitabine vs gemcitabine alone in metastatic pancreatic cancer: a Q-TWiST analysis. J Med Econ 2014;17:338–46.
   PubMedGoogle Scholar
• Li X, Hu W, Zheng X, Zhang C, Du P, Zheng Z, et al. Emerging immune checkpoints for cancer therapy. Acta Oncol 2015;54:1706–13.
   PubMed Web of Science ®Google Scholar
• Vaccaro V, Sperduti I, Vari S, Bria E, Melisi D, Garufi C, et al. Metastatic pancreatic cancer: Is there a light at the end of the tunnel? World J Gastroenterol 2015;21:4788–801.
   PubMed Web of Science ®Google Scholar
• Hurwitz HI, Uppal N, Wagner SA, Bendell JC, Beck JT, Wade SM, et al. Randomized, double-blind, phase II study of ruxolitinib or placebo in combination with capecitabine in patients with metastatic pancreatic cancer for whom therapy with gemcitabine has failed. J Clin Oncol 2015;33:4039–47.
   PubMed Web of Science ®Google Scholar